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Clinics and pathology 
Disease 
Precursor T-cell lymphoblastic lymphoma (T-ALL) 
with an association myeloproliferative neoplasm 
(MPN) with eosinophilia. 
Epidemiology 
Very rare; 1 case reported (Chmielecki et al., 2011). 
Clinics 
The patient was a 38 year-old male with a history of 
precursor T lymphoblastic lymphoma, a myeloid 
neoplasm associated neoplasm associated with 




The patient received a brief 5-day course of  
imatinib therapy, prior to allogenic stem cell 
transplantation, which resulted in resolution of his 
eosinophilia (white blood cell counts decreased from 
27.3 to 5.4 thou/µL; normal range (3.9-10.7 thou/µL). 
Prognosis 
In patients with myeloid neoplasms associated with 
eosinophilia, imatinib is also highly active against TK 
fusions involving PDGFRA and PDGFRB (David et 
al., 2007; Vardiman et al., 2009). 
 
 
Karyotype analysis of the bone marrow showed a translocation involving chromosomes 5 and 6: t(5;6)(q33-34;q23). 
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Fluorescence in situ hybridization (FISH) of a lymph node shows one split red signal (CSF1R-PDGFRB), one normal red signal, and two 
normal green signals (D5S23), suggesting existence of a rearrangement involving PDGFRB (LEFT). FISH analysis with a probe against 
MYB on chromosome 6 (marked by CEP 6 probe) shows one copy of MYB is now located on chromosome 5, suggesting involvement of 




The c6orf204-PDGFRB fusion protein fuses exon 11 of 
CEP85L/C6orf204 to exon 12 of PDGFRB. 
The cDNA breakpoint within PDGFRB is the same as 
that observed in the NIN-PDGFRB fusion, previously 
observed in another case of an imatinib-responsive 
myeloproliferative neoplasm (Vizmanos et al., 2004). 
The break within PDGFRB occurs just downstream of 
the transmembrane domain, removing the five 
immunoglobulin-like domains found within the 
extracellular domain but leaving the tyrosine kinase 
domain intact.  
The 5' sequence observed in our fusion protein could 
have resulted from two isoforms (a and c) arising from 
alternative transcriptional start sites and differing only 
in the first 24 amino acids. RT-PCR analysis using a  
anchored reverse primer and forward primers specific 
to isoforms a or c confirmed that the 5' sequence of the 
fusion originated from the isoform c start site. Motif 
analysis of C6orf204 revealed the presence of a coiled-
coil domain just N-terminal to the breakpoint observed 
in the C6orf204-PDGFRB fusion. The presence of a 
coiled-coil domain-containing 5' partner is a common 
occurrence in tyrosine kinase fusions involving 
PDGFRB and other tyrosine kianses (Vizmanos et al., 
2004), as it facilitates dimerization necessary for kinase 
(Carroll et al., 1996; Grisolano et al., 2003; Vizmanos 
et al., 2004; Taylor and Keating, 2005). The fusion here 
removes the last 8 amino acids of the domain. In vitro, 
a C6orf204-PDGFRB fusion product, generated via 
transient transfection of 293T cells with an expression  
plasmid, showed increased PDGFRB phosphorylation 
relative to mock transfected cells; such phosphorylation 
was inhibited by imatinib.  
Combined with the clinical response data, these studies 
indicate that the C6orf204-PDGFRB fusion is likely the 
'driver' of the patient's eosinophilia. 
Cytogenetics 
Cytogenetics molecular 
FISH analysis of the patient's lymph node suggested a 
rearrangement involving PDGFRB. 
Probes 
FISH was performed using standard procedures with 
CSF1R-PDGFRB (5q31-33 region) spectrum orange, 
D5S23 and D5S721 (5p15.2 region) spectrum green, 
and MYB (6q23) spectrum aqua unique sequence DNA 
probes and a chromosome 6 (D6Z1) spectrum green 
centromere probe (Abbott Molecular, Downers Grove, 
IL). 
Additional anomalies 
FISH analysis of the patient's diagnostic lymph node 
with T-ALL also revealed the presence of a PDGFRB 
rearrangement, suggesting that this event occurred in a 
common clonal precursor that gave rise to both the T-
ALL and eosinophilia. 
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Platelet-derived growth factor receptor beta (PDGFRb) 
is a catalytic receptor with intrinsic intracellular 
tyrosine kinase activity. It plays a role in the regulation 
of many biological processes including embryonic 
development, angiogenesis, cell proliferation and 
differentiation, and contribute to the pathophysiology 






The 5' sequence observed in our fusion protein could 
have resulted from two isoforms (a and c) arising from 
alternative transcriptional start sites and differing only 
in the first 24 amino acids. 
DNA/RNA 
13-14 exons (depending on isoform). 
Protein 
The gene encoding CEP85L/c6orf204 was originally 
identified as a breast cancer antigen (Scanlan et al., 
2001). 








Amino acids 1-677 of c6orf204 (isoform c) fused to 
amino acids 559-1106 of PDGFRB. 
Oncogenesis 
The patient's clinical response to imatinib therapy 
suggests that this fusion is the "driver" oncogene 
behind the eosinophilia. 
 
cDNA structure of the in-frame c6orf204-PDGFRB fusion. The resultant protein sequence is indicated below the cDNA sequence (TOP). 
Schematic showing the entire structure of the c6orf204-PDGFRB fusion protein including the coiled-coil domain within c6orf204 and the 
tyrosine kinase domain within PDGFRB. 
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